SCHEMBL2686464

SCHEMBL2686464

Cc1cc(-c2cc(NC(=O)[C@H](Cc3ccccc3)N(C)c3ccccn3)cc(OCCN(C)C)c2)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIP5K1C O60331 1/20 0.46
▸ GPR142 Q7Z601 2/20 0.43
▸ PSEN1 P49768 6/20 0.40
▸ PSEN2 P49810 6/20 0.40
▸ APH1B Q8WW43 6/20 0.40
▸ NCSTN Q92542 6/20 0.40
▸ APH1A Q96BI3 6/20 0.40
▸ PSENEN Q9NZ42 6/20 0.40
▸ WNT3A P56704 5/20 0.38
▸ PORCN Q9H237 1/20 0.38
▸ PPARG P37231 4/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ GMNN O75496 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ ADORA3 P0DMS8 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2686200 0.85 GPR142 (0.46) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2686466 0.83 GPR142 (0.58) PIP5K1CGPR142PSEN1PSEN2APH1B
SCHEMBL2686233 0.83 GPR142 (0.45) PIP5K1CGPR142PSEN1PSEN2APH1B
SCHEMBL2685595 0.76 GPR142 (0.52) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2685576 0.74 GPR142 (0.67) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2685659 0.73 GPR142 (0.53) PIP5K1CGPR142PSEN1PSEN2APH1B
Trifluoroacetic Acid SCHEMBL2685273 0.72 GPR142 (0.44) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2683468 0.69 GPR142 (0.47) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2686772 0.67 GPR142 (0.51) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2685644 0.67 ALDH1A1 (0.34) GPR142PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 — — US claimed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 — — US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 — — US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A PIP5K1C 2067/4885GPR142 2779/4885PSEN1 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback